Uh-oh! This study is no longer available.
Muscle-Invasive Bladder Cancer
PMG Research of DuPage Medical Group
18 or older
A research study is evaluating an investigational medication used in combination with Nivolumab (OPDIVO®) in those diagnosed with Muscle-Invasive Urothelial Carcinoma of the bladder.
This research study may be an option if you:
• Have a clinical diagnosis of muscle-invasive urothelial carcinoma of the bladder
• Are scheduled for radical cystectomy
• Are ineligible for or refusing platinum-based neoadjuvant chemotherapy
• Have adequate bone marrow, liver, and renal function
Other criteria apply. Please make sure to discuss with a member of our research staff to ensure this research study is a good fit for you.
Qualified participants will receive all study-related care and study medication at no cost.
Patient Commitment Duration
Approximately 7 months
Financial compensation may be provided for time and travel expenses.
Number of visits in study
Approximately 7 clinic visits